---
category: news
title: "Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC"
excerpt: "OnKai's AI models redefine the methodologies and economics of clinical trials TEL AVIV, Israel, July 10, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) (\"Galmed\" or the \"Company\"), a"
publishedDateTime: 2023-07-10T12:00:00Z
originalUrl: "https://www.benzinga.com/pressreleases/23/07/n33164058/galmed-to-employ-onkais-disruptive-artificial-intelligence-ai-in-its-planned-phase-2a-clinical-tri"
webUrl: "https://www.benzinga.com/pressreleases/23/07/n33164058/galmed-to-employ-onkais-disruptive-artificial-intelligence-ai-in-its-planned-phase-2a-clinical-tri"
ampWebUrl: "https://www.benzinga.com/amp/content/33164058"
cdnAmpWebUrl: "https://www-benzinga-com.cdn.ampproject.org/c/s/www.benzinga.com/amp/content/33164058"
type: article
quality: 54
heat: 54
published: false

provider:
  name: Benzinga.com
  domain: benzinga.com

topics:
  - AI in Healthcare
  - AI

images:
  - url: "https://www.benzinga.com/next-assets/images/schema-image-default.png"
    width: 1043
    height: 1043
    isCached: true

secured: "kOuJs2SmtV6HlcvqgWRwHAvZklmeYw/Dn3F/hdr6ygUaTAibAhFuWK/34cAzkEhsn4SBSn95FWwmXPIh77R8aAKya13oH+xy+ACoJNYiT2doA6iY9FJhdt3DYKr4lKTq6opR9Z2oCJ52FG/2ldfDRUEKRCClw4ZvAehGUDwkNHfualkg5BkeME5TiWNWYYb+HLBiR5tUqG6snc/W+wOktQHQ+cY50DHtC1y7dWQHPzsWbGwomh0bRoIs/LuRLrShlOcMbhkCB1iMV83oEsHUKZQ0tGbiwybSXaeMb+a0c4rry5z7VK43X1X/p85SqNWlSd92y+Kf5p6muYWB/BqZTG7/HsnELpUdYrceYxod0s8=;phwyWc/vjI40Co8pZFtDSA=="
---

